Introduction 1 2
Lung cancer is the most common cancer worldwide with the highest mortality rate (1). 3
The identification of therapeutic targets in non-small cell lung cancer (NSCLC), such as 4 epithelial growth factor receptor (EGFR)-activating mutations, has enabled the development 5 of effective targeted therapies for advanced NSCLC (2). However, the 5-year survival rate 6
for NSCLC remains 15% across all stages of the disease. These unfavorable clinical 7 outcomes originate from its high invasive and metastatic potential (3, 4). In particular, lung 8 adenocarcinoma (ADC) is known to establish distant macrometastases in various organs, 9 within months of diagnosis (5). Current targeted therapeutics have limited efficacy for the 10 treatment of distant metastases in lung ADC. 11
The short latency of metastatic relapse in lung ADC implies that the cancer cells in the 12 primary tumor have already acquired numerous multi-organ metastatic competencies, 13 including cell motility, invasiveness, resistance to hypoxia, enhanced angiogenesis, survival 14 after detachment, and evasion of immune surveillance (6, 7). Therefore, it might be possible 15 to identify predictive biomarkers of metastasis and novel therapeutic targets in primary ADCs 16 with high metastatic potential. These novel therapeutic targets could then be used to 17 overcome the resistance of NSCLC to currently available targeted treatments. 18
In our previous study, we compared the gene amplifications and deletions in lung ADCs 19 with synchronous brain metastasis to those in lung ADCs with metachronous brain 20 metastasis to elucidate the genomic alterations associated with early distant metastasis in 21 lung ADC (8). Among several genomic alterations, amplification of alpha-smooth muscle 22 actin (α-SMA; hereafter ACTA2) was significantly associated with synchronous brain 23 metastasis. ACTA2 is known to contribute to cell-generated mechanical tension and 24 maintenance of cell shape and movement. Since cell motility is critically dependent on the 
staining. 2
To confirm the expression of ACTA2 in lung ADC tumor cells, immunofluorescence was 3 performed with the mouse monoclonal anti-ACTA2 (Dako, 1:250) and rabbit polyclonal anti-4 thyroid transcription factor 1 (TTF-1) (abcam, 1:200) antibody against antigen-retrieved lung 5 ADC paraffin sections. TTF-1 has been reported to be one of several markers differentiating 6 ADC from squamous cell carcinoma of the lung (13) . The antibodies were visualized by 7
Alexa Fluor
® 488-labeled goat anti-mouse IgG and Alexa Fluor ® 594-labeled goat anti-rabbit 8
IgG antibody (Life Technologies), respectively. Samples were then incubated with DAPI 9
(1:1,000) for 5 mins at RT to reveal cell nuclei. SiRNAs directed against ACTA2, Focal adhesion kinase (FAK), and c-MET were purchased 2 from Santa Cruz Biotechnology. Control siRNA (siCTRL) was synthesized by Genolution. 3
For stable cell lines, cells were transfected with an ACTA2-specific shRNA (shACTA2, 4 Sigma) or empty pLKO vector (shCTRL) using Lipofectamine 2000, and then selected by 5 culturing in puromycin (5 μg/mL). 6 7
Western blot analysis and quantitative real-time PCR (RT-qPCR) 8
For western blot analysis, cells were lysed with RIPA buffer containing protease inhibitors 9 and phosphatase inhibitors (Roche). Equal amounts of protein were subjected to SDS-10 polyacrylamide gels electrophoresis and transferred to polyvinylidene difluoride (PVDF) 11 membranes (Millipore). After blocking in 5% bovine serum albumin (BSA), membranes were 12 incubated with the indicated primary antibodies overnight, and then with the appropriate 13 secondary antibodies. For RT-qPCR, total RNA was isolated using TRIzol reagent 14 (Invitrogen) according to the manufacturer's instructions, and then used to synthesize cDNA 15 with Superscript III Reverse Transcriptase (Invitrogen). Expression of mRNA was quantified 16 by RT-qPCR (ABI Prism 7600) using power SYBR ® Green PCR Master Mix (Applied 17 Biosystems). The primers used in this study were summarized in supplementary table S1. The number of invading cells on the lower surface of the membrane was counted. For experimental metastasis in vivo model, 2×10 5 cancer cells in 100 μL of HBSS were 1 directly injected into the left ventricle of the heart of 6~8 week-old female BALB/c nude mice 2 with a 1mL insulin syringe. Four weeks later, the animals were sacrificed. Brains, lungs, 3 lower leg bones, adrenal glands, and abnormal organs were harvested, fixed in formalin, and 4 embedded in paraffin. Paraffin-embedded tissues were stained with H&E. 5 6
Statistical analysis 7
Overall survival and metastasis-free survival were calculated by the Kaplan-Meier method 8
and compared by the log-rank test. Group comparisons were analyzed with Student's two-9 tailed t-test. Tumor metastasis rates were compared by Fisher's exact test, two-tailed. 10
Differences with P values less than 0.05 were considered statistically significant. To confirm the role of ACTA2 in the metastasis of lung ADC, we assayed ACTA2 4 expression in 263 lung ADCs by immunohistochemistry (Fig. 1A) . When more than 50% of 5 tumor cells expressed ACTA2, the patients were considered as ACTA2-High (n=14). 6
Specific detection of ACTA2 protein was verified by same staining patterns of two different 7 antibodies against human ACTA2 (Supplementary Fig. S1 ). Moreover, ACTA2 protein in 8 lung ADC cells was confirmed by co-localization of ACTA2 with a lung ADC specific marker, 9 TTF-1 (Fig. 1B) . The stromal ACTA2 expression in immunohistochemistry (Fig. 1A) and the 10 presence of ACTA2-positive, TTF-1-negative cells in immunofluorescence staining (Fig. 1B We generated 7 PC14PE6 lung ADC cell subclones that stably express 6 different ACTA2 1 shRNAs or a control vector (pLKO) to assess the effect of ACTA2 silencing on the metastatic 2 potential of lung ADC cells. Downregulation of ACTA2 mRNA and protein was confirmed by 3 RT-qPCR ( Fig. 2A and Supplementary Fig. S2 ) and western blot analysis (Fig. 2B) , 4 respectively. When ACTA2 expression was downregulated by shRNA, the migration (Fig. 2C  5 and Supplementary Fig. S2 ) and invasion ( Fig. 2D and Supplementary Fig. S2 ) of 6 PC14PE6 cells were significantly inhibited. Since PC14PE6 cells transfected with 7
shACTA2#6 showed the lowest expression of ACTA2 mRNA and strong suppression of 8 migration and invasion, PC14PE6/shACTA2#6 cells (hereafter, PC14PE6/shACTA2) were 9 used for all subsequent experiments. The inhibitory effects of ACTA2 silencing on the in vitro 10 migration potential of lung ADC cells were confirmed using various lung ADC cell lines and a 11 specific siRNA targeting ACTA2 (Supplementary Fig. S3) . 12 ACTA2 downregulation also significantly decreased transendothelial migration (TEM, Fig.  13 3A), and clonogenicity (Fig. 3B ) of PC14PE6 cells, properties that are required for distant 14 metastasis of lung cancer. In contrast, proliferation (Supplementary Fig. S4A ), anoikis-15 resistance (Supplementary Fig. S4B) , and adhesion to fibronectin [an extracellular matrix 16 Fig. S4C ) of PC14PE6 cells were not affected by the 17 shRNA-mediated ACTA2 downregulation. Therefore, the inhibitory effects of ACTA2 18 silencing on the migration and invasion of PC14PE6 cells did not result from decreased 
significantly affected those processes, which indicated that ACTA2 could be required for 1 distant metastasis of lung ADC. To investigate whether ACTA2 has the effect on primary 2 lung tumorigenesis in vivo, 1×10 6 control (PC14PE6/shCTRL) or ACTA2 knockdown 3 (PC14PE6/shACTA2) cells were implanted into the subcutaneous tissue (PC14PE6/shCTRL, 4 n=7; PC14PE6/shACTA2, n=7) or left lung (PC14PE6/shCTRL, n=7; PC14PE6/shACTA2, 5 n=6) of nude mice. In the subcutaneous model, both tumor growth rate (P=0.43) and final 6 tumor weight (P=0.49) were not significantly affected by ACTA2 downregulation (Fig. 4A) . 7 ACTA2 downregulation also made no effects on the tumor formation in the lung cancer 8 orthotopic model, since the survival of mice with intralung injection of PC14PE6/shACTA2 9 cells (median survival length=32 days) was comparable to that of the control group (median 10 survival length=25 days) (Fig. 4B, P=0.318) . These results are consistent with that of the in 11 vitro cell proliferation assay, which firmly validates no significant role of ACTA2 in lung 12
tumorigenesis. 13
To further examine the in vivo biological role of ACTA2 in the metastatic potential of lung 14 ADC cells, we injected 1×10 6 PC14PE6/shCTRL or PC14PE6/shACTA2 cells into the left 15 ventricle [systemic metastasis animal model; PC14PE6/shCTRL (n=9), PC14PE6/shACTA2 16 (n=7)] of nude mice. In contrast to the tumorigenicity assays, significantly less metastatic 17 potential was observed in mice that received an intracardiac injection of PC14PE6/shACTA2 18 cells (Fig. 4C) . These mice had a sole metastatic tumor in the adrenal gland (14% incidence, 19 1/7 mice), whereas mice that received an intracardiac injection of PC14PE6/shCTRL cells 20 had a 78% incidence (7/9 mice) of metastatic tumors, and the metastatic sites varied [lung, 21 adrenal gland, bone, brain, and eyeball] (Fig. 4C) . Each metastatic tumor was confirmed 22 pathologically (Fig. 4D) . These in vivo assays indicated that ACTA2 promotes lung ADC 23 metastasis without affecting primary tumor formation potential, which would be mediated by 24 increased migration, invasion, and clonogenicity of lung ADC cells. 
Effects of ACTA2 on FAK and c-MET expression 1
From the above results, we determined that ACTA2 is a critical factor for the acquisition of 2 metastatic potential in lung ADC cells. To address the mechanism whereby ACTA2 3 regulates metastatic potential, we analyzed the expression of EMT-associated proteins, such 4 as FAK and c-MET, since EMT is a critical process for acquisition of metastatic potential. 5 PC14PE6 cells were transfected with an ACTA2-specific siRNA. Forty eight hours after the 6 transfection, mRNA and protein of both FAK and c-MET were significantly decreased (Fig.  7   5A ). ACTA2 silencing also significantly increased E-cadherin expression and decreased 8 vimentin expression (Fig. 5B) . These results indicated that the expression of FAK and c-9
MET, which are major signaling molecules for metastasis, is suppressed by ACTA2 10 downregulation, and that ACTA2 expression is required for maintenance of the Fig. S5 ). Similarly to ACTA2 silencing, silencing of either FAK and 18 c-MET inhibited migration (Fig. 5C) and invasion (Fig. 5D) 
to predict clinical aggressiveness of lung ADC, which were demonstrated in this report and 1 our previous study (8), respectively. 
